Pfizer heart pill to be standalone therapy

Jul 26, 2006

U.S.-based Pfizer Inc., the world's largest pharmaceutical company, says it has decided to sell a new heart treatment medication as a standalone pill.

Pfizer initially announced it would sell the new drug, torcetrapib, only in combination with Lipitor, the company's best-selling cholesterol treatment medication, The New York Times reported. That decision produced strong opposition from physicians.

Torcetrapib, still being tested in clinical trials, is at least 18 months from receiving federal approval. But initial trial results indicate the drug substantially raises the levels of so-called good cholesterol -- a novel approach to preventing heart attacks and strokes, the Times said.

If Pfizer had offered torcetrapib only in a combination pill, that would have forced patients taking other cholesterol-lowering statins -- such as Merck & Co. Inc.'s Zocor -- to switch to Lipitor to obtain torcetrapib's benefits.

If proven effective, industry observers say the drug could potentially garner several billion dollars annually in sales.

Copyright 2006 by United Press International

Explore further: Sleep apnea treatment is effective for older people

add to favorites email to friend print save as pdf

Related Stories

FDA adds heart warning to Pfizer anti-smoking pill

Jun 16, 2011

(AP) -- Federal health regulators are warning doctors and patients that Pfizer's anti-smoking drug Chantix may slightly increase the risk of heart attack and other cardiovascular problems.

Hormone-blocking drug reduces breast cancer risk

Jun 04, 2011

(AP) -- Millions of women at higher-than-usual risk of breast cancer have a new option for preventing the disease. Pfizer Inc.'s Aromasin cut the risk of developing breast cancer by more than half, without the side effects ...

UNICEF discloses vaccine prices for 1st time

May 29, 2011

UNICEF is for the first time publicizing what drugmakers charge it for vaccines, as the world's biggest buyer of lifesaving immunizations aims to spark price competition in the face of rising costs.

Recommended for you

Exercising restraint to stall tumor growth

16 minutes ago

Many proteins undergo an assembly line-style process of glycosylation as they travel from a cellular structure called the endoplasmic reticulum (ER) to the Golgi apparatus and on through its various compartments, ...

Seniors face barriers to critical dental care

26 minutes ago

Research has shown that poor oral health can have a negative impact on seniors' overall health and well-being, but for many, there are significant barriers to visiting a dentist, finds a new report in the ...

Hospitals should follow CDC recommendations for Ebola care

46 minutes ago

(HealthDay)—Hospital and health care providers should follow the U.S. Centers for Disease Control and Prevention's recommendations for care of patients with Ebola, according to an ideas and opinions piece ...

User comments : 0